Evidence map›Paper›PMID 41694575›Full record

ArticleInternational journal of biological sciences2026

FKBP10 promotes M2 polarization of macrophage via MEK/ERK/CXCL8 axis and facilitates tumor progression in clear cell renal cell carcinoma.

Jin-Wei Chen, Jia-Ying Li, Hao-Qian Feng, Liang-Min Fu, Xin-Wei Zhou, Han-Sen Lin, Ying-Han Wang, Ke-Zhi Liu, Yu-Hang Chen, Zhu Wang and 7 more

Abstract read
In one paragraph

Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jin-Wei ChenDepartment of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Jia-Ying LiDepartment of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Hao-Qian FengDepartment of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Liang-Min FuDepartment of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xin-Wei ZhouDepartment of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Han-Sen LinDepartment of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Ying-Han WangDepartment of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Ke-Zhi LiuDepartment of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Yu-Hang ChenDepartment of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Zhu WangDepartment of Urology, Affiliated Longhua People's Hospital, Southern Medical University, Shenzhen, Guangdong, China.
Qiong DengDepartment of Urology, Affiliated Longhua People's Hospital, Southern Medical University, Shenzhen, Guangdong, China.
Jie-Yan WangDepartment of Urology, Affiliated Longhua People's Hospital, Southern Medical University, Shenzhen, Guangdong, China.
Mei-Yu JinDepartment of Urology, Affiliated Longhua People's Hospital, Southern Medical University, Shenzhen, Guangdong, China.
Hui LiangDepartment of Urology, Affiliated Longhua People's Hospital, Southern Medical University, Shenzhen, Guangdong, China.
Jin-Huan WeiDepartment of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Jun-Hang LuoDepartment of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Cheng-Peng GuiDepartment of Urology, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The progression and therapeutic response of clear cell renal cell carcinoma (ccRCC) are critically shaped by the complex interactions between tumor cell heterogeneity and the tumor immune microenvironment (TIME). However, a comprehensive classification of the ccRCC ecosystem and its clinical relevance is lacking. To address this, we utilized comprehensive bioinformatics approaches to analyze ten public single-cell RNA sequencing datasets from 194 samples across 118 ccRCC patients. Across 1,172,154 cells, we identified four TIME subtypes (immune activation, innate immunity, immunosuppressive myeloid [ISM], and immune exclusion) and six functional states of tumor cells (metabolic, angiogenic, stress-responsive, antigen-presenting, cell cycling, and epithelial-mesenchymal transition [EMT]). The interplay between these components defined four immune ecosystems, among which the ISM subtype, coupled with the EMT tumor state was associated with the poorest prognosis. Using machine learning-based prognostic modeling, we highlighted FKBP10 as a critical prognostic gene. Mechanistically, we demonstrated that FKBP10 not only promoted EMT but also activated the MEK/ERK/ELF3 signaling axis, leading to an increased secretion of CXCL8 by tumor cells. Tumor-derived CXCL8, in turn, drove macrophage M2 polarization and myeloid-derived suppressor cell (MDSC) recruitment, thereby reinforcing an immunosuppressive TIME. Furthermore, targeting FKBP10 synergized with anti-PD-1 therapy in suppressing tumor growth

Indexed as

Carcinoma, Renal CellInterleukin-8Kidney NeoplasmsMacrophagesTacrolimus Binding ProteinsAnimalsCell Line, TumorDisease ProgressionEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansMAP Kinase Signaling SystemMiceTumor MicroenvironmentInterleukin-8Tacrolimus Binding Proteinsanti-PD-1/PD-L1 therapyclear cell renal cell carcinomaFKBP10tumor heterogeneitytumor microenvironment

Identifiers

PMID41694575
PMCPMC12905587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.